<DOC>
	<DOC>NCT01828008</DOC>
	<brief_summary>To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.</brief_summary>
	<brief_title>Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas</brief_title>
	<detailed_description>Autologous CIK transfusion within 3 days post CD20 antibody treatment.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>diagnosed as Bcell lymphoma with CD20 positiveness, and need to therapy to refuse the therapy and need not tolerate the therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Mabthera</keyword>
	<keyword>cytokine induced killer cell</keyword>
</DOC>